Journal of Chemotherapy最新文献_第2页

Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer.

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-03-24 DOI: 10.1080/1120009X.2025.2481349

Junji Koyama, Masahiro Morise, Ichidai Tanaka, Sho Hori, Reiko Matsuzawa, Sachiko Ozone, Akihiro Matsushita, Masaki Matsuo, Shuichi Asano, Taro Tanaka, Koichiro Shima, Tomoki Kimura, Koji Sakamoto, Yasuhiro Kondoh, Naozumi Hashimoto

{"title":"Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer.","authors":"Junji Koyama, Masahiro Morise, Ichidai Tanaka, Sho Hori, Reiko Matsuzawa, Sachiko Ozone, Akihiro Matsushita, Masaki Matsuo, Shuichi Asano, Taro Tanaka, Koichiro Shima, Tomoki Kimura, Koji Sakamoto, Yasuhiro Kondoh, Naozumi Hashimoto","doi":"10.1080/1120009X.2025.2481349","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2481349","url":null,"abstract":"The benefit of programmed cell death protein-1 (PD-1)/programmed cell death protein ligand-1 (PD-L1) inhibitors remains unclear in non-small cell lung cancer (NSCLC) patients with poor performance status (PS). In the current multi-centre retrospective cohort study, advanced or recurrent NSCLC patients treated with PD-1/PD-L1 inhibitors were enrolled. Of the 219 patients enrolled, 44 had PS 2-4. The objective response rate (ORR) of patients with PS 2-4 in 1st line was 33%. Among 1st line group, median progression-free survival (PFS) in patients with PS 2 was significantly longer compared to that in patients with PS 3-4 (15.3 months vs. 0.9 months, P = 0.039, Log-rank test). Among previously treated patients, the ORR of patients with PS 2-4 was only 4%, and PFS and overall survival was poor even in patients with PS 2. PD-1/PD-L1 inhibitors can be an option for PS 2 NSCLC patients in 1st line setting.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Concurrent inhibition of FLT3 and sphingosine kinase-1 triggers synergistic cytotoxicity in midostaurin resistant FLT3-ITD positive acute myeloid leukemia cells via blocking FLT3/STAT5A signaling to induce apoptosis.

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-03-21 DOI: 10.1080/1120009X.2025.2478340

Melisa Tecik, Aysun Adan

{"title":"Concurrent inhibition of FLT3 and sphingosine kinase-1 triggers synergistic cytotoxicity in midostaurin resistant FLT3-ITD positive acute myeloid leukemia cells via blocking FLT3/STAT5A signaling to induce apoptosis.","authors":"Melisa Tecik, Aysun Adan","doi":"10.1080/1120009X.2025.2478340","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2478340","url":null,"abstract":"The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) is one of the most frequent mutations observed in acute myeloid leukemia (AML) which contributes to disease progression and unfavorable prognosis. Midostaurin, a small FLT3 inhibitor (FLT3I), is clinically approved. However, patients generally possess acquired resistance when midostaurin used alone. Shifting the balance in the sphingolipid rheostat toward anti-apoptotic sphingosine kinase-1 (SK-1) or glucosylceramide synthase (GCS) is related to therapy resistance in cancer, however, their role in midostaurin resistant FLT3-ITD positive AML has not been previously investigated. We generated midostaurin resistant MV4-11 and MOLM-13 cell lines which showed increased IC50 values compared to their sensitive partner cells. SK-1 is overexpressed in resistant cells while GCS remains unchanged. Subsequent pharmacological targeting of SK-1 in resistant cells decreased SK-1 protein level, inhibited cell proliferation and showed additive or synergistic effect on cell growth, as confirmed by the Chou-Talalay combination index, and induced G0/G1 arrest (PI staining by flow cytometry). Cotreatment (SKI-II plus midostaurin) triggered apoptosis via phosphatidylserine exposure (annexin V/PI double staining). Mechanistically, induction of the intrinsic pathway of apoptosis was confirmed as increased activating cleavages of caspase-3 and PARP and increased Bax/Bcl-2 ratios. Activating phosphorylations of FLT3 (at tyrosine residue 591) and STAT5A (at tyrosine residue 694) dramatically inhibited in resistant cells treated with the combination. In conclusion, midostaurin resistance could be reversed by dual SK-1 and FLT3 inhibition in midostaurin resistant AML cell lines, providing the first evidence of a novel treatment approach to re-sensitize FLT3-ITD positive AML.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-17"},"PeriodicalIF":1.9,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143677042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of nausea induced by trifluridine/tipiracil in metastatic colorectal cancer treatment. 评估转移性结直肠癌治疗中曲氟啶/替吡嘧啶引起的恶心。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-03-20 DOI: 10.1080/1120009X.2025.2479901

Yoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara

{"title":"Evaluation of nausea induced by trifluridine/tipiracil in metastatic colorectal cancer treatment.","authors":"Yoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara","doi":"10.1080/1120009X.2025.2479901","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2479901","url":null,"abstract":"Trifluridine/tipiracil (FTD/TPI) frequently induces chemotherapy-induced nausea and vomiting (CINV). As evidence of factors associated with CINV in oral chemotherapeutic agents is limited, we aimed to assess factors for nausea development in a real-world FTD/TPI-containing treatment for metastatic colorectal cancer (mCRC). Patients with mCRC receiving FTD/TPI with or without bevacizumab (n = 104) were retrospectively evaluated. Nausea occurred in 40.4% of the patients, and the severity was grade 1 for 23.1%, grade 2 for 15.4%, and grade 3 for 1.9%. Multivariable logistic regression analysis suggested that female sex (adjusted odds ratio 2.74, 95% confidence interval 1.02-7.33, p = 0.045) and concomitant bevacizumab (2.68, 1.13-6.37, p = 0.03) were independent risk factors for all-grade nausea during the first cycle as a primary endpoint. Particularly, among patients with FTD/TPI monotherapy, females significantly exhibited nausea compared to males. Our study revealed that concomitant bevacizumab and female sex are independent risk factors for nausea in FTD/TPI-containing treatment for mCRC.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":1.9,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mpox: there is still risk of global outbreak.

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-03-13 DOI: 10.1080/1120009X.2025.2476830

Silvano Esposito, Chiara D'Amore, Flora Salzano, Pasquale Pagliano

引用次数: 0

Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes in breast cancer patients: a systematic review study.

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-28 DOI: 10.1080/1120009X.2025.2468044

Ali Tayebi, Adnan TizMaghz, Mahmood Gorjizad, Arian Tavasol, Ali Tajaddini, Fariborz Rashnoo, Kimia Vakili, Mohsen Behmanesh, Faranak Olamaeian, Mohammadjavad Ashoori

{"title":"Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes in breast cancer patients: a systematic review study.","authors":"Ali Tayebi, Adnan TizMaghz, Mahmood Gorjizad, Arian Tavasol, Ali Tajaddini, Fariborz Rashnoo, Kimia Vakili, Mohsen Behmanesh, Faranak Olamaeian, Mohammadjavad Ashoori","doi":"10.1080/1120009X.2025.2468044","DOIUrl":"10.1080/1120009X.2025.2468044","url":null,"abstract":"As a systematic review, this study addresses a gap in the literature by evaluating both the short-term and long-term outcomes of breast cancer patients undergoing neoadjuvant chemotherapy (NAC). The purpose of the current study was to evaluate NAC's impact on breast cancer patients' surgical outcomes. We performed a comprehensive search of international databases, including PubMed, Scopus, Embase, and Science Direct, covering studies from 2000 to 2023, using carefully selected keywords. Our search strategy aimed to capture a wide variety of relevant studies. To ensure a structured and unbiased selection, we followed PRISMA guidelines throughout the process. We concentrated on identifying studies that reported on short-term outcomes, like surgical complications (e.g., operation time, blood loss), as well as long-term outcomes, including overall survival, tumor size reduction, metastasis rates, breast conservation surgery, and recurrence rates. The findings highlighted the benefits of NAC in terms of lower recurrence and metastasis rates. The results also emphasized the significance of considering tumor characteristics and nodal involvement for prognostication in this patient population. The findings of this study will contribute to a better understanding of the impact of NAC on surgical outcomes in breast cancer patients, providing valuable insights for treatment planning and optimizing patient care.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":1.9,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the role of quercetin on doxorubicin and lapatinib-mediated cellular and mitochondrial responses using in vitro and in silico studies.

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-23 DOI: 10.1080/1120009X.2025.2471154

Ali Ergüç, Gökay Albayrak, Muhammed Tilahun Muhammed, Fuat Karakuş, Ege Arzuk, Elif İnce-Ergüç

{"title":"Exploring the role of quercetin on doxorubicin and lapatinib-mediated cellular and mitochondrial responses using in vitro and in silico studies.","authors":"Ali Ergüç, Gökay Albayrak, Muhammed Tilahun Muhammed, Fuat Karakuş, Ege Arzuk, Elif İnce-Ergüç","doi":"10.1080/1120009X.2025.2471154","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2471154","url":null,"abstract":"Doxorubicin (DOX) and lapatinib (LAP) have been reported to cause liver toxicity. The roles of mitochondrial and cellular responses in DOX and LAP mediated-hepatotoxicity have not been investigated with or without quercetin (QUE) in HepG2 cells sensitive to mitochondrial damage (high-glucose or galactose media) in addition to in silico studies. Our results revealed that cytosolic pathways might play role a in DOX-induced cytotoxicity rather than mitochondria. QUE exacerbated DOX-induced ATP depletion in both environments. Our data also indicated that cytosolic and mitochondrial pathways might play a role in LAP-induced cytotoxicity. Incubating QUE with LAP increased ATP levels in high-glucose media. Therefore, QUE might have protective effect against LAP-induced cytotoxicity resulting from cytosolic pathways. The findings from in vitro experiments that QUE increased DOX or LAP-induced mitochondrial dysfunction were confirmed by the results from in silico studies indicating that QUE incubated with LAP or DOX might increase mitochondrial dysfunction.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-15"},"PeriodicalIF":1.9,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The relationship between body mass index and survival in patients with renal cell carcinoma treated with nivolumab.

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-23 DOI: 10.1080/1120009X.2025.2469371

Rumeysa Çolak, İlkay Gültürk, Gülhan Dinç, Goncagül Akdağ, Sedat Yıldırım, Mesut Yılmaz, Deniz Tural

{"title":"The relationship between body mass index and survival in patients with renal cell carcinoma treated with nivolumab.","authors":"Rumeysa Çolak, İlkay Gültürk, Gülhan Dinç, Goncagül Akdağ, Sedat Yıldırım, Mesut Yılmaz, Deniz Tural","doi":"10.1080/1120009X.2025.2469371","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2469371","url":null,"abstract":"Introduction: Immunotherapies have increased the therapeutic options for patients with metastatic renal cell carcinoma (mRCC), but the absence of prognostic indicators remains unresolved. We assessed the potential association of BMI with the overall survival (OS) of patients treated with nivolumab.Methods: We performed a retrospective study of 126 patients with histologically confirmed mRCC who began systemic ICI therapy between January 2016 and April 2022 were included. BMI at the time of treatment start was calculated. Then patients were divided into two groups: high BMI (≥25) and low BMI (<25). Therapeutic responses were determined according to RECIST v1.1. OS was defined as the time from starting ICI treatment until death or last follow-up at the data cutoff.Results: The cohort was male 74.6%, with a median age of 62. The median follow-up time was 18.6 months. The patients were classified as low BMI (<25) and high BMI (≥25). The OS was 40.6 months (95% CI: 34.2-47.0) for patients with high BMI vs. 9.4 months (95% CI: 7.0-11.7) for patients with low BMI, and a significant association was found between BMI and OS (p < 0.001).Conclusions: BMI was an independent prognostic factor in the patients with mRCC treated with nivolumab. Prospective and multicenter research is needed to confirm our findings.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Syrian generic ceftriaxone sodium preparations for injection: BHT content and its implications.

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-21 DOI: 10.1080/1120009X.2025.2468046

Abeer Srour, Khawla Alamere, Ghassan Abo Chameh, Basima Arous, Mohammad Amer Al-Mardini

{"title":"Comparison of Syrian generic ceftriaxone sodium preparations for injection: BHT content and its implications.","authors":"Abeer Srour, Khawla Alamere, Ghassan Abo Chameh, Basima Arous, Mohammad Amer Al-Mardini","doi":"10.1080/1120009X.2025.2468046","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2468046","url":null,"abstract":"This study aimed to evaluate the compatibility of generic ceftriaxone sodium preparations with various rubber closures used in pharmaceutical packaging, focusing on the release of butylated hydroxytoluene (BHT), an antioxidant present in rubber closures that may migrate into drug products. BHT levels were quantified using gas chromatography-mass spectrometry (GC-MS) to assess stability and safety. Results showed that all samples contained BHT, with concentrations ranging from below the quantification limit to a maximum of 5.65 ppm. Notably, 47.62% of the samples exceeded the threshold of toxicological concern (TTC) of 1.5 µg/day, raising significant safety concerns. Older samples exhibited higher BHT levels, and products from pharmacies generally had greater concentrations than those obtained from manufacturers. These findings underscore the critical importance of assessing interactions between drug formulations and packaging materials, emphasizing the need for rigorous quality control in injectable pharmaceuticals. Future research should explore strategies to mitigate BHT accumulation in these preparations.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.9,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful treatment with oxaliplatin and programmed cell death protein 1 inhibitor in recurrent advanced endometrial carcinoma with mismatch repair defects: a case report and literature review.

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-21 DOI: 10.1080/1120009X.2025.2466274

Jian Qiu, Tian Ding, Mingyue Cao, Xiaohong Huang, Yinfeng Wang

引用次数: 0

Investigation of chemotherapy-induced cardiac dysfunction in breast cancer. 乳腺癌化疗诱发心功能障碍的研究。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-20 DOI: 10.1080/1120009X.2025.2466278

Sai Harini Chandrasekaran, Pugazhendi Inban, Reeju Maharjan, Ansari Maha Faisal, Vishva Maheshbhai Patel, Ewuradjoa Ayirebi-Acquah, Venkata Sai Harsha Bhargav Chenna, Hend Makky, Misbah Kamal Khan, Rohan Raj, Jubran Al Hooti, Sofia Alik, Parvinder Kaur, Keti Solomnishvili, Shree Rath

{"title":"Investigation of chemotherapy-induced cardiac dysfunction in breast cancer.","authors":"Sai Harini Chandrasekaran, Pugazhendi Inban, Reeju Maharjan, Ansari Maha Faisal, Vishva Maheshbhai Patel, Ewuradjoa Ayirebi-Acquah, Venkata Sai Harsha Bhargav Chenna, Hend Makky, Misbah Kamal Khan, Rohan Raj, Jubran Al Hooti, Sofia Alik, Parvinder Kaur, Keti Solomnishvili, Shree Rath","doi":"10.1080/1120009X.2025.2466278","DOIUrl":"10.1080/1120009X.2025.2466278","url":null,"abstract":"Although recent advancements in cancer treatment have significantly improved survival rates, they have also raised concerns regarding severe adverse effects, including cardiotoxicity. We conducted a prospective study at Dayanand Medical College and Hospital, Ludhiana to assess chemotherapy-related cardiac dysfunction in newly diagnosed, histologically confirmed breast cancer cases. Among 97 breast cancer patients undergoing chemotherapy, 13 (13.4%) developed left ventricular dysfunction (LVD), predominantly in younger patients with left-sided breast involvement (64.9%). A significant association was found between estrogen receptor (ER) positivity and LVD risk (P = 0.03), with 15.4% of LVD patients also being hypertensive. The incidence of LVD was notably high at 38.5% among patients receiving trastuzumab, while cumulative doses of doxorubicin and cyclophosphamide did not show significant correlation with LVD. Recovery was promising, with 76.9% of affected patients demonstrating significant improvement post-treatment. These findings highlight the need for continuous cardiac monitoring and personalized treatment strategies to mitigate LVD risk.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":1.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0